Teva Pharmaceutical (TEVA) Enters Into a License Agreement With Prestige Biopharma for the Commercialization of Tuznue in Europe

Group 1 - Teva Pharmaceutical Industries Limited (NYSE:TEVA) is recognized as an affordable stock option under $20, with a recent license agreement for the commercialization of Tuznue, a biosimilar to Herceptin, in most European markets [1][2] - Tuznue is an approved treatment for breast cancer and metastatic gastric cancer, with marketing authorization from the European Commission expected in September 2024 [2] - The license and supply agreement grants Teva rights to distribute and market Tuznue in Europe, utilizing its extensive commercial network and expertise in biosimilars, while Prestige Biopharma will handle production and supply from its EU-GMP-certified facilities [3] Group 2 - Teva operates in various geographical segments, including the US, Europe, and International Markets, covering a comprehensive product portfolio that includes specialty, generics, and over-the-counter (OTC) products [4]